Neonc Technologies Stock (NASDAQ:NTHI)

Revenue Financials Chart

Previous Close

$7.10

52W Range

$4.11 - $25.00

50D Avg

$7.83

200D Avg

$7.83

Market Cap

$140.42M

Avg Vol (3M)

$79.76K

Beta

-

Div Yield

-

NTHI Company Profile

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Mar 26, 2025

Website

NTHI Performance

NTHI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$83.00K	$70.46K	$20.00K
Operating Income	$-7.14M	$-12.20M	$-2.84M
Net Income	$-11.90M	$-14.92M	$-3.05M
EBITDA	$-9.10M	$-12.20M	$-2.85M
Basic EPS	$-0.63	$-0.80	$-0.16
Diluted EPS	$-0.63	$-0.80	$-0.16

Fiscal year ends in Dec 24 | Currency in USD